Contingency Management for PrEP Adherence and/or Methamphetamine Use (C-MAX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04563962|
Recruitment Status : Recruiting
First Posted : September 25, 2020
Last Update Posted : April 27, 2021
|Condition or disease||Intervention/treatment||Phase|
|Methamphetamine-dependence HIV-1-infection||Behavioral: Contingency Management-ART Behavioral: Contingency Management-Methamphetamine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Contingency Management for PrEP Adherence and/or Methamphetamine UseDisorder Among MSM and TW in Los Angeles: A Pilot Feasibility Study|
|Actual Study Start Date :||March 15, 2021|
|Estimated Primary Completion Date :||July 31, 2021|
|Estimated Study Completion Date :||July 31, 2021|
Experimental: Contingency Management-ART
Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
Behavioral: Contingency Management-ART
Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
Active Comparator: Contingency Management-Methamphetamine
Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
Behavioral: Contingency Management-Methamphetamine
Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
- PrEP/ART Adherence [ Time Frame: 28 days ]Proportion of visits in which there are detectable levels of tenofovir in participant urine samples.
- Methamphetamine Abstinence [ Time Frame: 28 days ]Proportion of visits in which there are no detectable methamphetamine metabolites in participant urine samples.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04563962
|Contact: Jesse L Clark, MDemail@example.com|
|United States, California|
|UCLA Vine Street Clinic||Recruiting|
|Los Angeles, California, United States, 90038|
|Contact: Christopher Blades 323-461-3106|
|Principal Investigator:||Jesse L Clark, MD||University of California, Los Angeles|
|Principal Investigator:||Monica Gandhi, MD||University of California, San Francisco|